Valuation: Exelixis, Inc.

Market Cap 16.98B 15.23B 13.91B 12.7B 23.93B 1,596B 24.69B 168B 66.88B 851B 63.72B 62.35B 2,688B P/E 2026 *
20.2x
P/E 2027 * 17.1x
Enterprise Value 16.03B 14.38B 13.14B 12B 22.6B 1,507B 23.31B 158B 63.16B 804B 60.18B 58.89B 2,539B EV / Sales 2026 *
6.27x
EV / Sales 2027 * 5.3x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day+1.25%
1 week+0.26%
Current month+0.26%
1 month+19.05%
3 months+28.67%
6 months+50.55%
Current year+58.73%
1 week 68.01
Extreme 68.01
73.69
1 month 58.59
Extreme 58.59
73.69
Current year 39.71
Extreme 39.71
73.69
1 year 39.71
Extreme 39.71
73.69
3 years 19.2
Extreme 19.2
73.69
5 years 14.87
Extreme 14.87
73.69
10 years 13.09
Extreme 13.09
73.69
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+1.25%+0.26%+70.47%+229.56% 16.98B
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.14%+2.41%+51.31%+190.35% 42.37B
Weighted average by Cap. +0.68%+2.96%+50.73%+168.43%

Financials

2026 *2027 *
Net sales 2.56B 2.29B 2.09B 1.91B 3.6B 240B 3.72B 25.25B 10.07B 128B 9.59B 9.39B 405B 2.88B 2.58B 2.36B 2.15B 4.06B 270B 4.18B 28.42B 11.33B 144B 10.8B 10.57B 455B
Net income 895M 803M 734M 670M 1.26B 84.13B 1.3B 8.84B 3.53B 44.89B 3.36B 3.29B 142B 1.02B 916M 837M 764M 1.44B 96.02B 1.49B 10.09B 4.02B 51.23B 3.83B 3.75B 162B
Net Debt -943M -846M -773M -706M -1.33B -88.67B -1.37B -9.32B -3.72B -47.31B -3.54B -3.46B -149B -1.74B -1.56B -1.43B -1.3B -2.45B -164B -2.53B -17.2B -6.86B -87.33B -6.54B -6.4B -276B
Projected Income Statement - Annual - Exelixis, Inc.
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-11-06 $69.57 +1.25% 2,003,609
26-11-05 $68.71 -5.55% 4,376,151
26-11-04 $72.75 +0.61% 3,014,149
26-11-03 $72.31 +3.11% 3,849,479
26-11-02 $70.13 +1.07% 5,590,567
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Exelixis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
69.57USD
Average target price
61.57USD
Spread / Average Target
-11.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Exelixis, Inc.
  1. Stock Market
  2. Stocks
  3. EXEL Stock